No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VTR240719P42500
- 0.07
- 0.000.00%
15min DelayClose Jun 25 10:53 ET
0.00High0.00Low
0.00Open0.07Pre Close0 Volume15 Open Interest42.50Strike Price0.00Turnover1218.26%IV20.94%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.0271Delta0.0097Gamma766.71Leverage Ratio-5.2228Theta0.0000Rho-20.79Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
Express News | Ventas Inc : Scotiabank Raises Target Price to $55 From $52
Express News | Ventas Inc : BMO Raises Target Price to $60 From $57
Real Estate Stocks Gain as Traders Look for Alternatives to Tech Stocks
(VTR) - Analyzing Ventas's Short Interest
Ventas Announces Second Quarter 2024 Earnings Release Date and Conference Call
Ventas Is Maintained at Outperform by Evercore ISI Group
Comments
Analyst Connor Siversky predicts OHI and NHI's rent coverage will increase due to improving portfolio metrics. However, he doubts VTR's senior housing portfolio improvement will offset high leverage and limited investment opportunities. He also suggests OHI's dividend will be covered in late 2024, and NHI is set to drive growth with a strong liquidity profile.
Omega Healthcare, National Health Investors Upgraded to Overweight at Wells Fargo 1
follow for daily top watchlist ⭐️
$Apyx Medical(APYX.US$ $Addentax(ATXG.US$ $Axsome Therapeutics(AXSM.US$ $BioXcel Therapeutics(BTAI.US$ $Baudax Bio(BXRX.US$ $CymaBay Therapeutics(CBAY.US$ $CorMedix(CRMD.US$ $Marriott International(MAR.US$ $Microvision(MVIS.US$ $Renalytix(RNLX.US$ $State Street(STT.US$ $Treehouse Foods(THS.US$ $Targa Resources(TRGP.US$ $VBI Vaccines(VBIV.US$ $Ventas Inc(VTR.US$
$Apyx Medical(APYX.US$ $Addentax(ATXG.US$ $Axsome Therapeutics(AXSM.US$ $BioXcel Therapeutics(BTAI.US$ $Baudax Bio(BXRX.US$ $CymaBay Therapeutics(CBAY.US$ $CorMedix(CRMD.US$ $Marriott International(MAR.US$ $Microvision(MVIS.US$ $Renalytix(RNLX.US$ $State Street(STT.US$ $Treehouse Foods(THS.US$ $Targa Resources(TRGP.US$ $VBI Vaccines(VBIV.US$ $Ventas Inc(VTR.US$
1
$Affirm Holdings(AFRM.US$ initiated at neutral by Compass Point, announced target price at $15.00.
$SoFi Technologies(SOFI.US$ initiated at sell by Compass Point, announced targe price at $5.00.
$Evotec(EVO.US$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price from $12.00 to $16.00.
$Principal Financial(PFG.US$ was upgraded by Jefferies from underperform to hold, increased target price from $60.00 to $6...
$SoFi Technologies(SOFI.US$ initiated at sell by Compass Point, announced targe price at $5.00.
$Evotec(EVO.US$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price from $12.00 to $16.00.
$Principal Financial(PFG.US$ was upgraded by Jefferies from underperform to hold, increased target price from $60.00 to $6...
15
Upgrades
• $Advanced Micro Devices(AMD.US$ : Northland Capital Upgrades to Outperform from Market Perform - PT $95
• $Bunge(BG.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $140)
• $Brookfield Infrastructure Partners LP(BIP.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $49.50
• $Banco Santander Chile(BSAC.US$ : UBS Upgrades to Neutral from Sell - PT $18 (from $17)
• $Crown Castle(CCI.US$ : Jefferi...
• $Advanced Micro Devices(AMD.US$ : Northland Capital Upgrades to Outperform from Market Perform - PT $95
• $Bunge(BG.US$ : BofA Securities Upgrades to Buy from Neutral - PT $135 (from $140)
• $Brookfield Infrastructure Partners LP(BIP.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $49.50
• $Banco Santander Chile(BSAC.US$ : UBS Upgrades to Neutral from Sell - PT $18 (from $17)
• $Crown Castle(CCI.US$ : Jefferi...
18
2
Read more